Syros Pharmaceuticals (SYRS) Misses Q3 EPS by 11c
Get Alerts SYRS Hot Sheet
Join SI Premium – FREE
Syros Pharmaceuticals (NASDAQ: SYRS) reported Q3 EPS of ($0.65), $0.11 worse than the analyst estimate of ($0.54).
Cash and cash equivalents as of September 30, 2016 were $93.5 million, compared with $35.9 million on December 31, 2015. The increase in cash includes the net proceeds from the Company’s IPO that closed in July 2016 and its Series B preferred stock offering that closed in January 2016, offset primarily by approximately $32.9 million in cash to fund operations and purchase equipment. Syros expects that its current cash and cash equivalents balance will be sufficient to fund its operating expenses and capital expenditure requirements into mid-2018.
For earnings history and earnings-related data on Syros Pharmaceuticals (SYRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lockheed Martin (LMT) Tops Q1 EPS by 53c, Beats on Revenue; Offers FY24 Guidance
- Fiserv (FI) Tops Q1 EPS by 9c; Boosts outlook
- Lockheed Martin (LMT) Tops Q1 EPS by 59c, Beats on Revenue; Offers FY24 Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, IPOSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!